semaglutide canada patent expiry Novo Nordisk to lose blockbuster drug patent over small fee

Last week's expiry of the patent for semaglutide—the active ingredient in Novo Nordisk's blockbuster drugs that are used to treat both diabetes and obesity—unleashed a flurry of launches of low-cost generic versions

27.87

★★★★☆4.8 (126)

Canada approves generic semaglutide from Dr. Reddy's, a G7 first enabled by Novo Nordisk's lapsed CAD$250 patent

22.40

★★★★★4.9 (98)

Semaglutide — the powerhouse ingredient behind Novo Nordisk’s Ozempic and Wegovy is on the verge of patent expiry in 2026. Starting January 4, Canada will become the first market to allow generic

23.82

★★★★★5.0 (157)

As the patent for semaglutide, the key ingredient in the popular weight-loss drug Ozempic, is set to expire in March, Indian pharmaceutical giants are gearing up to flood the market with generic

20.96

★★★★★4.7 (84)

The semaglutide story: highlighting the need to maintain patent protection in Canada

29.62

★★★★★4.9 (203)

The upcoming expiry of the semaglutide patent in India in mid-March 2026 is expected to transform the country's diabetes treatment landscape. Ahead of this, industry experts predict that the development will open

21.36

★★★★★5.0 (176)

Semaglutide (Ozempic) Market: Navigating The Patent Cliff And Strategic Implications

27.63

★★★★★4.8 (132)